Companies

See how salaries can vary from company to company

Sertoma Center is dedicated to serving adults with developmental disabilities through providing the highest quality of residential, vocational and community services that empower the persons served to lead richer, fuller lives. Sertoma Center was founded in 1961 by the Knoxville Downtown Sertoma Club and met in the basement of First Presbyterian Church. The initial goal of the Center was to train pre-school children for special education classes in the public schools and originally served 17 children. In 1970, the move was made to Dandridge Avenue and the Center was established as a non-profit... view company details

Singing River Health System is the community based, not-for-profit healthcare provider for Jackson County and surrounding areas on the Gulf Coast. As one of the county's largest employers, the system offers award-winning, comprehensive care for every age and stage. Singing River Health System is committed to the highest quality standards and is an accredited Blue Cross Blue Shield Center of Excellence. We provide both critical and acute health services, charitable assistance, and lead numerous educational and community outreach programs. We strengthen the local economy by recruiting more than ... view company details

TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS. Its Ublituximab is a novel anti-CD20 monoclonal antib... view company details

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense. Its lead product candidate is Tonmyar (TNX-102 SL), a proprietary low-dose cyclobenzaprine and sublingual tablet as a bedtime administration, which is in Phase III development for the treatment of posttraumatic stress disorder (PTSD) and Fibromyalgia; and Phase II development for the treatment of agitation in Alzheimer's disease. The company is also developing TN... view company details

Internationally accredited by CARF/CCAC, Fitch rated, and neighbor to the Duke University campus and medical center, The Forest at Duke is a vibrant, not-for-profit 501(c)3 continuing care retirement community. Over 800 residents from 38 different states have chosen to call The Forest home since its opening in 1992. Today, 400 people enjoy life at The Forest and over 250 team members are an integral part of their lives. Residents are professors, gardeners, authors, CEOs, community volunteers, opera buffs, engineers, librarians, homemakers, artists - folks from all walks of life who embrace and... view company details

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various patholo... view company details

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD101 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotempora... view company details

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-d... view company details

Valley Health is a not-for-profit health system dedicated to meeting the medical needs of West Virginia, Maryland, and the Top of Virginia. With award-winning hospitals, advanced medical services, and cutting-edge technology, Valley Health has been recognized as a leader in healthcare services. We care about giving back and bringing together communities to provide the care local residents need. Our system's history goes back to 1903, when our first hospital opened its door with just 36 beds. Now, with a combined 604 inpatient beds, 166 long-term care beds, 5,300 employees, and 500 medical staf... view company details

White Mountains Insurance Group, Ltd., through its subsidiaries, provides insurances services in the United States. The company operates through four segments: HG Global/BAM, NSM, MediaAlpha and Other Operations. The HG Global/BAM segment provides insurance on municipal bonds issued to finance public purposes, such as schools, utilities, and transportation facilities, as well as reinsurance protection services. The NSM segment operates as a general underwriting agency and property administrator for specialty property and casualty insurance to sectors, such as specialty transportation, social s... view company details

Windtree Therapeutics, Inc., a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and drug-delivery technologies being developed to enable the noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that has completed Phase IIb clinical trial to treat respiratory distress sy... view company details

ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to f... view company details

WHO WE ARE: Briogeo is currently the fastest growing hair care product line at Sephora and has taken the prestige hair care world by storm through introducing clients to an assortment of clean - yet effective - hair care products for all hair texture types. Briogeo has won numerous awards, including accolades from Allure Best of Beauty / Reader's Choice, O' The Oprah Magazine, Seventeen Magazine, Essence Magazine, New Beauty, and recently won a coveted award for Best Indie Hair Care Brand by CEW. Briogeo products have been featured in global press publications such as Vogue, Allure, Elle, Glam... view company details

Genesis Financial, Inc. purchases and resells seller financed real estate receivable contracts. The company will initially focus on purchasing residential and commercial real estate receivables contracts and business notes from $25,000 to $250,000 in value, and it may broker larger transactions. As the business grows, Genesis intends to expand its services to include larger contracts and other forms of cash flow investment instruments. The company will purchase contracts from holders at a discount to the face amount, and after a short holding period, it will resell the contracts, typically a... view company details

8x8, Inc. provides enterprise cloud communications and customer engagement solutions for small and mid-size businesses, mid-market, and distributed enterprises worldwide. It offers unified communications, team collaboration, conferencing, contact center, analytics, and other services to various business customers on a software-as-a-service (SaaS) model. The company provides 8x8 Virtual Office, a self-contained and end-to-end solution that delivers high quality voice and unified communications-as-a-service; 8x8 Contact Center, a multi-channel cloud-based contact center solution; and 8x8 Meeting... view company details

Astea International Inc. develops, markets, and supports service management software solutions worldwide. It offers Astea Alliance, a service management software that addresses the service lifecycle applications, including lead generation, project quotation, service and billing, and asset retirement; and integrates and optimizes business processes for campaigns, call center, depot repair, field service, logistics, projects, and sales and order processing applications. The company also provides FieldCentrix Enterprise suite, a service management solution that runs on various mobile devices; and... view company details

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including ... view company details

Amkor Technology, Inc. provides outsourced semiconductor packaging and test services in the United States and internationally. The company offers turnkey packaging and test services, including semiconductor wafer bumps, wafer probes, wafer back-grinds, package design, packaging, and test and drop shipment services. Its packages employ wirebond, flip chip, copper clip, and other interconnect technologies. The company also provides semiconductor testing services, such as wafer and final test services; flip chip scale package products for use in smartphones, tablets, and other mobile consumer ele... view company details

Altra Industrial Motion Corp. designs, produces, and markets a range of electromechanical power transmission motion control products for use in motion related applications, and high-volume manufacturing and non-manufacturing processes worldwide. It operates in two segments, Power Transmission Technologies and Automation & Specialty. The Power Transmission Technologies segment offers couplings, such as gear couplings, diaphragm and disc couplings, elastomeric couplings, miniature and precision couplings, joints, mill spindles, and shaft locking devices under the Ameridrives, Bibby, Guardian, Hu... view company details

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of pati... view company details